NOVAREMED
Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019.
“This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.”
Poster Presentation Details:
Presentation Title:
Novaremed is developing NRD.E1, an innovative
therapy for diabetic neuropathic pain - Results from a proof of concept
study
https://www.novaremed.com/wp-content/uploads/2019/05/PS90_Novaremed_NRDE1PoCinDNP_20190503_c.pdf
Presenter:
Sara Mangialaio, MD, PhD, Novaremed
Presentation Date:
May
11, 2019
Notes to the Editor:
About Novaremed
Novaremed Ltd. was founded in 2008 in Israel
and reincorporated as Novaremed AG in Switzerland late 2017. Novaremed
is developing NRD.E1, an orally-active small molecule with a
differentiated mechanism of action for the treatment of Diabetic
Neuropathic Pain (DPN). In a Phase 2a Proof of Concept study, NRD.E1
showed clinically relevant reduction in patient reported pain. Novaremed
is currently preparing for a global Phase 2b study in DPN, expected to
start in Q4 2019. For more information, visit www.novaremed.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190517005176/en/
Contact:
Subhasis Roy Chief Operating Officer Tel: +41 79 2075715 Email: subhasis.roy@novaremed.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FLATEXDEGIRO-AG25.4.2024 20:20:33 CEST | Press release
flatexDEGIRO Starts Into Expected Record Year 2024 With a Jump in Revenues and Earnings
CA-OPENGATE-CAPITAL25.4.2024 19:15:32 CEST | Press release
OpenGate Capital Completes Sale of SMAC
FARCANA25.4.2024 17:41:30 CEST | Press release
Farcana Announces Gateway: Showdown - Playtest Kicks Off April 30th, with a 1,000,000 $FAR token prize pool!
ANTOGNOLLA25.4.2024 16:40:29 CEST | Press release
Antognolla at International Hospitality Investment Forum: Growing Interest in the Italian Market from Hotel Operators and Investors
CA-LASERFICHE25.4.2024 16:31:29 CEST | Press release
Digital Transformation’s Next Era: Generative AI and Laserfiche 12 at 2024 Empower Conference
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom